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Background: In some Dutch pancreatic surgery centers, patients who underwent pan-
creatoduodenectomy (PD) for ampullary cancer undergo surveillance for colorectal cancer (CRC), since an
association is suggested in contemporary literature. This study aimed to examine the CRC incidence after
PD for ampullary cancer in four pancreatic surgery centers and a Dutch nationwide cohort.
Methods: All patients who underwent resection of ampullary cancer from 2005 through 2017 at four
centers were included. All colonoscopies and CRC diagnoses in these patients were recorded. In addition
all PDs for ampullary cancer in the Dutch Pathology Registry (2000e2017) were recorded along with the
CRC diagnoses and compared with an age, sex, and year-matched cohort.
Results: Out of 287 included patients by the four centers, 11% underwent a colonoscopy within one year
after PD. Eight (2.7%) were diagnosed with CRC before PD and two (0.7%), at 14 and 72 months after PD.
In the nationwide cohort comparison, the CRC incidence was similar before (2.6% versus 1.9%, P¼ 0.424)
and after surgery (2.1% versus 3.1%, P¼ 0.237). Within one year after PD, the incidence was 0.3%
compared to 0.6% in the matched controls (P¼ 0.726).
Conclusions: The current study could not find an increased risk of CRC in patients with resected
ampullary cancer. Therefore, there is insufficient justification to screen for CRC in patients with resected
ampullary cancer.
© 2019 Published by Elsevier Ltd.Introduction
Ampullary cancer is a rare malignancy that accounts for
approximately 0.2% of all gastrointestinal cancers [1]. Due to its
origin distal to the bile and pancreatic duct confluence at the
duodenal outflow, the onset of symptoms (e.g. biliary obstruction)
is early compared to most other periampullary and pancreatic tu-
mors. As a consequence, resection rates of ampullary cancers reach
up to 92% [2] and the reported 5-year survival rates range from 38
to 67% [3e5].smus Medical Center, Doctor
ands.
f).
eening for colorectal cancer a
/j.ejso.2019.10.013Several reports have suggested an increased incidence of colo-
rectal polyps and malignancies in patients with ampullary cancer.
Ampullary cancer in some patients is associated with hereditary
colorectal cancer (CRC) syndromes, such as hereditary non-
polyposis colorectal cancer (HNPCC) [6] and familial adenoma-
tous polyposis (FAP) [7e9]. However, in ampullary cancer patients
without these syndromes, the CRC incidence is also reported to be
higher than in age-adjusted control groups [10,11].
This association has led to colorectal surveillance in patients
who underwent pancreatoduodenectomy (PD) for ampullary can-
cer in some pancreatic cancer centers in the Netherlands. The yield
of routine colonoscopy within one year after surgery is subject of
debate.




Age, years, median (IQR) 68 (60e74)






ASA score, n (%)
III-IV 42 (15)
Pyloris preserving PD, n (%) 203 (71)
Minimally invasive approach, n (%)
Laparoscopic 2 (1)
Robotic 3 (1)
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pancreatic surgery centers. Subsequently, the incidence of CRC was
investigated in the Dutch nationwide pathology database.
Methods
All consecutive patients who underwent PD from January 2005
through December 2017 at four Dutch pancreatic surgery centers
with a diagnosis of ampullary cancer were included. All patients
were selected from prospectively maintained databases at the in-
dividual centers based on the postoperative final pathology reports.
Patients with benign or premalignant (i.e. dysplasia without inva-
sion) disease of the ampulla and patients diagnosed with either FAP
or HNPCCwere excluded. All additional datawas retrieved from the
electronic medical records. The need of ethical approval and the
need for individual informed consent was waived by the institu-
tional medical ethics committee.
Primary outcome
All colonoscopy procedures in the patient cohort both before
and after PD were reviewed and scored. The procedural data and
number of found and biopsied colorectal polyps were scored, and
the outcomes at pathology were recorded. In addition, both pre-
vious diagnoses of CRC in the patient cohort before surgery were
scored, as were all diagnoses of CRC during follow up after PD.
Variables
All postoperative complications within 30 days after surgery
were scored and graded according the classification proposed by
Dindo et al., with major complications defined as grade III or higher
[12]. The incidence of postoperative pancreatic fistula [13], biliary
leakage, was scored and graded according to the respective ISGPS
definitions. Readmissionswithin 30 days after surgery and 90-
mortality were scored as other outcome parameters.
Survival was defined as the time between the PD and date of
death or last follow up. Recurrence-free survival was defined as
time from PD to the diagnoses of recurrence, usually on imaging
studies. In order to identify subgroups of patients with inferior
prognosis in which the relevance of CRC screening would be less
relevant, prognostic variables such as TNM stage (7th edition),
differentiation grade, and resection margin were recorded.
Dutch Pathology Registry
Due to the centralization of pancreatic surgery in the
Netherlands, patients are usually referred for surgery to a pancre-
atic surgery center. Follow-up can be conducted either at the
pancreatic surgery center or at the referral center. Colonoscopies
performed outside the pancreatic surgery center might have been
missed. Therefore, all patients who underwent PD between 2000
and 2017 with ampullary cancer as pathology diagnosis were
extracted from the nationwide network and registry of histo- and
cytopathology in the Netherlands (PALGA) [14]. All diagnoses of
colorectal polyps and malignancies were linked to these patients.
Using this strategy all patients nationwide were identified along
with all their colorectal pathology diagnosis conducted in any
hospital nationwide.
A matched control group was selected from patient who un-
derwent diagnostic excision of a mole. These control patients were
matched based on a similar 5-year age category at time of the
procedure, sex, and the year of the procedure (i.e., diagnostic
excision of a mole or pancreaticoduodenectomy). All colorectal
diagnoses before and after the mole excision were identified andPlease cite this article as: Olthof PB et al., Screening for colorectal cancer a
of Surgical Oncology, https://doi.org/10.1016/j.ejso.2019.10.013scored.
Statistical analysis
Continuous data were presented as median with inter-quartile-
range (IQR), except for survival durations which were presented as
median with 95% confidence intervals (95%CI). Categorical data
were presented as number (percentages) and differences were
tested using chi-square of Fisher's exact tests. Survival curves were
generated according to the Kaplan Meier method and curves were
compared using log-rank tests. Length of follow-up was estimated
using the reverse Kaplan Meier method. All statistical analyses
were performed using SPSS (Version 23.0, IBM, Chicago, IL) and




In the study period, 289 patients underwent PD for ampullary
cancer. Two patients diagnosed with a hereditary polyposis syn-
drome were excluded and the remaining 287 patients were
included in the analyses. Baseline characteristics are provided in
Table 1 and postoperative outcomes in Table 2. Median (95% CI)
follow up was 83 months (64e104), with a median (95% CI) overall
survival of 35 (25e45) months and 5-year survival was 40%.
Eight patients (2.7%) were diagnosed with CRC before PD, seven
had colon cancer and the remaining two had rectal cancer. All
underwent curative resection with a median (range) of 39 (22e70)
months before PD and a single patient underwent additional
curative resection of colorectal liver metastases 74 months before
ampullary cancer resection.
Thirty-three patients (11%) underwent a colonoscopy within
one year after PD all with surveillance as indication. The proportion
of patients who underwent a colonoscopy within one year ranged
from 3% to 15% across the four included centers (P¼ 0.064). In nine
of these procedures, no polyps were found and 22 procedures
resulted in the resection or biopsy of hyperplastic polyps or polyps
with low grade dysplasia. No CRC was diagnosed within one year of
PD. During subsequent follow-up of these 33 patients none were
diagnosed with CRC.
During further follow-up an additional 14 patients underwent a
colonoscopy. Two of these (0.7%) patients were diagnoses with CRC
(Fig. 1). The first patient was diagnosed with rectal cancer 14
months after PD and underwent curative resection of a T1N0 tumor,
the other patient had a right-sided colonic tumor 72 months after










V (30-day mortality 16 (6)
Postoperative pancreatic fistula, n (%)
Grade B/C 62 (22)
Biliary leakage, n (%)
Grade B/C 19 (7)
Readmission rate, n (%) 29 (10)
90-day mortality, n (%) 18 (6)





Node positive disease, n (%) (n ¼ 286) 140 (49)
Tumor size, mm, median (IQR) (n ¼ 282) 20 (15e30)




R0 resection rate, n (%) 257 (90)
Fig. 1. Overall survival in the 287 patients who underwent pancreatoduodenectomy
for ampullary cancer. The two diagnoses of colorectal cancer during follow up are
indicated by the arrows. Below the graph are the number of patients at risk.
P.B. Olthof et al. / European Journal of Surgical Oncology xxx (xxxx) xxx 3cancer during staging.
Considering amedian (95% CI) follow-up of 83 (64e104)months
after PD in the 287 patients, the person years follow-up was 1044
years. Consequently, there was 1 CRC event per 522 person years of
follow-up.
Dutch Pathology Registry cohort
From the Dutch Pathology Registry, 901 patients were identified
who underwent PD for ampullary cancer between 2000 and 2017,
which includes the four-center cohort of 287 patients mentioned
above. Twenty-three (2.6%) out of the 901 patients were diagnosed
with CRC before PD, all of whom underwent curative resection. One
of these patients was treated for a primary colon cancer twicePlease cite this article as: Olthof PB et al., Screening for colorectal cancer a
of Surgical Oncology, https://doi.org/10.1016/j.ejso.2019.10.013before PD. Sixty-six patients (7%) underwent a colonoscopy with a
biopsy for pathology analysis within one year after PD. In three of
these patients, CRC was diagnosed. For one of these patients, this
was a second primary colon cancer. During subsequent follow-up,
an additional 66 (7%) patients underwent colonoscopy with a bi-
opsy. In sixteen of these patients, CRC was diagnosed and one pa-
tient had a colonic lesion that turned out to be a ampullary cancer
metastasis. This translates into a postoperative CRC incidence of
2.1% (19/901). The diagnosis of adenocarcinoma was made at a
median follow-up of 3 (2e6) years after PD.
The results from the ampularry cancer patients were compared
to 901 control patients who underwent diagnostic excision of a
mole, matched for age, sex, and the year of surgery (Table 3). In the
matched cohort, 17 (1.9%) patients were diagnosed with CRC before
the diagnostic excision(P¼ 0.424). Five patients were diagnosed
with CRC within one year after surgery (P¼ 0.726). In the matched
cohort, the postoperative CRC incidence was 3.1% (28/901) diag-
nosed at a median follow-up of 4 (2e8) years after mole excision
(P¼ 0.237).Overall, 39 (4.7%) ampullary cancer patients were
diagnosed with CRC either before or after surgery compared to 45
(5.0%) in the control group (P¼ 0.826).
Discussion
This study reports on 287 patients who underwent PD for
ampullary cancer. Thirty-three (11%) patients underwent a colo-
noscopy either the year of or year after ampullary cancer surgery
and none of these procedures CRC was diagnosed. Two (1%) pa-
tients were diagnosed with CRC, 14 and 72 months after PD. At a
national level, 901 patients underwent PD for ampullary cancer
over an 18 year period. The incidence of CRC after PD was similar
(2.1%) to a matched control group (3.1%, P¼ 0.237). Within one year
after surgery, the CRC incidence was 0.3% and 0.6% (P¼ 0.0726),
respectively.
Patients diagnosed with familiar adenomatous polyposis syn-
drome have an increased lifetime risk of 3e4% for duodenal cancer
including ampullary cancer [15]. Duodenal malignancies are the
main cause of cancer-related death in these patients, which is why
these patients undergo routine surveillance for duodenal tumors
[8,16]. Hereditary non polyposis CRC is also associated with an
increased risk of ampullary cancer [6]. To what extent sporadic
ampullary cancer is associated with colorectal polyps and malig-
nancies is less well defined.
Several case reports and case series have reported on the inci-
dence of ampullary cancer in association with other tumors,
particularly CRC [17e20]. More recent studies showed similarities
in pathogenesis between ampullary and CRC, including similar
genetic alterations [20,21]. A report including 7 cases of ampullary
cancer and 19 ampullary adenomas found colorectal polyps in 23%
of patients compared to 26% in an age-matched control group [10].
However, there were two cases of CRC in the ampullary group and
none in the control group, therefore the authors suggested colo-
rectal screening in the work-up for ampullary neoplasms. A larger
report identified 2043 patients with pathology confirmed ampul-
lary cancer, of which 30 (1.4%) developed CRC during follow up as
opposed to 14 expected cases based on age-related incidence,
resulting in a two-fold higher incidence [11].
Although these studies report on an increased incidence of CRC
in ampullary cancer patients, the clinical relevance of the diagnoses
and colorectal screening is unknown. The present study found 19
cases of CRC after resection of ampullary cancer in 901 patients,
which translates into a 2.1% incidence, which was slightly higher
compared to the 1.4% in the study by Das et al. In the four-center
cohort, the CRC incidence after PD was one per 522 person
follow-up years, compared to 189 after PD and 405 in the controlfter pancreatoduodenectomy for ampullary cancer, European Journal
Table 3
Comparison of the CRC after PD for ampullary cancer and the matched control group from PALGA: Dutch Pathology Registry.
Ampullary cancer patients Matched controls P-value
CRC diagnosis, n (%)
Before surgery 23 (2.6) 17 (1.9) 0.424
Within one year of surgery 3 (0.3) 5 (0.6) 0.726
After surgery 19 (2.1) 28 (3.1) 0.237
Total 42 (4.7%) 45 (5.0) 0.826
P.B. Olthof et al. / European Journal of Surgical Oncology xxx (xxxx) xxx4group in the Das et al. report, which included both resected and
unresected ampullary cancer patients, compared to resected pa-
tients in the present study. Since the prognosis of unresected
ampullary cancer is dismal with no long-term survival [22], the
follow-up of the present cohort is likely longer and since patients
have to be alive to be diagnosed with CRC this has likely influenced
the differences.
The CRC incidence in the age-matched control group was 3.1%,
which was slightly higher but non-significant compared to the
ampullary cancer group. This could be to the likely inferior prog-
nosis of the ampullary cancer patients compared to the control who
underwent diagnostic excision of a mole. Due to the set-up of the
PALGA registry that includes only pathology diagnoses, no median
follow-up duration was available. Nevertheless, the 2.1% in the
intervention group compared to the 3.1% incidence in the control
group does not support a clinically relevant increased risk of CRC
after PD for ampullary cancer, especially since the overall incidence
of CRC before or after the reference procedure was similar both
cohorts.
Only three patients out of 901 were diagnosed with CRC within
one year after PD. This suggests a standard screening of CRC in these
patients does not outweigh the associated adverse effects of colo-
noscopy such as bleeding and perforation and the associated costs
[23,24]. Especially since the incidence in the control group was 5
diagnoses out of the 901 patients who underwent diagnostic
excision of a mole, in which no physicianwould consider screening
for colorectal polyps.
Median overall survival was 36 (27e46) months after resection
and 5-year overall survival was 40%. Survival is strongly influenced
by positive lymph nodes, resection margin, tumor grade, as well as
lymphovascular, and perineural invasion [25,26]. In the presence of
any of these factors, survival is poor. Conversely, in patients with a
radical resection of a well differentiated tumor with negative
lymph nodes might have long term survival. Considering the sur-
vival rates in the presence of one of more of these prognostic fac-
tors, all efforts to screen for colorectal polyps will likely not impact
the outcomes for these patients.
This report has several limitations. The main limitation is the
retrospective study design which, considering the low amount of
patients that underwent colonoscopy, is subject to verification bias.
However, the nationwide pathology data is of high quality due to
the all-inclusive nationwide data which included diagnoses of
colorectal polyps of these patients in any hospital and revealed
similar results. Finally, since a colonoscopy and/or biopsy had to be
performed in order to include the colorectal diagnoses in the
report, it cannot be excluded that some patients with (asymp-
tomatic) CRC were missed. Furthermore, some patients might have
been part of the colorectal cancer screening program using stool
sampling implemented in the Netherlands for all inhabitants ages
55 to 75 starting January 2014.
In conclusion, 2.1% of patients who undergo PD for ampullary
cancer are diagnosed with CRC during follow-up. Since only 3 pa-
tients were diagnosed within one year of surgery, compared to 5
patients after diagnostic mole excision, standard perioperative
screening of CRC in these patients is likely irrelevant. Especially inPlease cite this article as: Olthof PB et al., Screening for colorectal cancer a
of Surgical Oncology, https://doi.org/10.1016/j.ejso.2019.10.013patients with advanced tumor stage or tumor-related characteris-
tics associated with poor prognosis, the relevance of (asymptom-
atic) CRC is questionable due to the limited prognosis. The current
study could not find an increased risk of colorectal malignancies in
patients with resected ampullary cancer. Therefore, there is insuf-
ficient justification to screen for colorectal polyps andmalignancies
in patients with resected ampullary cancer.
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